Safety, efficacy of KPI-121 0.25% for DED treatment

December 18, 2020
David Hutton

,
Alex Delaney-Gesing

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of dry eye disease in patients enrolled in four trials.

See more AAO coverage

Related Content:

AAO | Dry Eye | Clinical Diagnosis